Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients.
Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients.
复制标题
DOI：
10.1136/annrheumdis-2012-201800
复制
发表时间：
2014-01
影响因子：
27.4
通讯作者：
Oddis CV
中科院分区：
文献类型：
--
作者：
Aggarwal R;Cassidy E;Fertig N;Koontz DC;Lucas M;Ascherman DP;Oddis CV
比较Jo-1和非Jo-1抗tRNA合成酶自身抗体(抗SynAb)患者的累积生存期和无事件生存期。从1985年到2009年初步评估的抗联体抗体阳性患者被纳入，而不考虑结缔组织病(CTD)的诊断。临床数据提取自前瞻性收集的数据库和图表回顾。采用对数秩法和COX比例风险法比较Jo-1和非Jo-1患者的生存率。抗突触抗体阳性202例，其中Jo-1 122例，非Jo-1 80例(PL-12 35例，PL-7 25例，EJ 9例，KS 6例，OJ 5例)。Jo-1和非Jo-1患者初诊诊断分别为肌炎83%和40.0%，重叠或未分化CTD分别为17%和47.5%，系统性硬化症分别为0%和12.5%(p<；0.001)。Jo-1患者的诊断延迟中位数为0.4年，而非Jo-1患者的中位延迟时间为1.0年(p<；0.001)。在整个队列中最常见的死亡原因是肺纤维化(49%)和肺动脉高压(11%)。Jo-1患者的5年和10年未调整累积生存率分别为90%和70%，而非Jo-1患者分别为75%和47%(p<；0.005)。与Jo-1患者相比，非Jo-1患者的累积风险比(HR)为1.9(p=0.01)，诊断后无事件生存的风险比(HR)为1.9(p=0.008)。首次诊断年龄和延迟诊断影响生存率，但与性别、种族和CTD诊断无关。与Jo-1患者相比，非Jo-1抗SynAb阳性患者的存活率降低。存活率的差异可能部分归因于非Jo-1患者的诊断延迟。
To compare the cumulative survival and event free survival in patients with Jo-1 versus non-Jo-1 anti-tRNA synthetase autoantibodies (anti-synAb). Anti-synAb positive patients initially evaluated from 1985 to 2009 were included regardless of the connective tissue disease (CTD) diagnosis. Clinical data were extracted from a prospectively collected database and chart review. Survival between Jo-1 and non-Jo-1 was compared by log rank and Cox proportional hazards methods. 202 patients possessed anti-synAb: 122 Jo-1 and 80 non-Jo-1 (35 PL-12; 25 PL-7; 9 EJ; 6 KS; 5 OJ). The diagnoses at first visit for Jo-1 and non-Jo-1 patients were myositis in 83% and 40.0%, overlap or undifferentiated CTD in 17% and 47.5%, and systemic sclerosis in 0% and 12.5%, respectively (p<0.001). The median delay in diagnosis was 0.4 years in Jo-1 patients versus 1.0 year in non-Jo-1 patients (p<0.001). The most common causes of death in the overall cohort were pulmonary fibrosis in 49% and pulmonary hypertension in 11%. The 5- and 10-year unadjusted cumulative survival was 90% and 70% for Jo-1 patients, and 75% and 47% for non-Jo-1 patients ( p<0.005). The hazard ratio (HR) of non-Jo-1 patients compared with Jo-1 patients was 1.9 (p=0.01) for cumulative and 1.9 (p=0.008) for event free survival from diagnosis. Age at first diagnosis and diagnosis delay but not gender, ethnicity and CTD diagnosis influenced survival. Non-Jo-1 anti-synAb positive patients have decreased survival compared with Jo-1 patients. The difference in survival may be partly attributable to a delay in diagnosis in the non-Jo-1 patients.
登录
查看更多内容
影响因子：
3.6
作者：
Chen, Yi-Ju;Wu, Chun-Ying;Shen, Jui-Lung
通讯作者：
Shen, Jui-Lung
影响因子：
5.5
作者：
Sato, S.;Kuwana, M.;Hirakata, M.
通讯作者：
Hirakata, M.
影响因子：
5.5
作者：
Sultan, SM;Ioannou, Y;Isenberg, DA
通讯作者：
Isenberg, DA
影响因子：
4.7
作者：
Chatterjee, Soumya;Farver, Carol
通讯作者：
Farver, Carol
影响因子：
4.3
作者：
Fischer, Aryeh;Swigris, Jeffrey J.;Brown, Kevin K.
通讯作者：
Brown, Kevin K.